EHA 2024 | Indirect comparison of elranatamab in MagnetisMM-3 versus real-world treatment regimens
Luciano Costa
• 2 Jun 2024
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses an indirect comparison of outcomes for patients with multiple myeloma (MM) treated with elranatamab in the MagnetisMM-3 trial (NCT04649359) versus real-world treatment regimens. The analysis indicates that elranatamab provides a greater frequency and longer duration of response in patients compared to other regimens, making it a potential option for triple-class exposed (TCE) patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
